Aging

Beast Games star and matchmaker Tessa Mac shares her powerful journey into regenerative medicine, sparked by a friend’s cancer battle and solidified by her own "aha" moment regarding biological insurance. In the inaugural episode of Future Proof with Forever Labs podcast, she shares why she decided to freeze her Mesenchymal Stem Cells (MSCs) as the ultimate "low-hanging fruit" for long-term health. From setting world records to surviving California wildfires, Tessa explains how securing her youngest, healthiest cells allows her to live a high-octane life today with zero regrets for tomorrow.

Explore Forever Labs's outlook on 2026 trends in regenerative medicine. Longevity has transitioned from biohacking to a mainstream standard of care. Discover breakthroughs in "bio-liquidity", MSC priming, and epigenetic resetting, alongside regulatory shifts in the United States empowering patients to own their biology.

Aging is a complex process of damage accumulation, and has been viewed as experimentally and medically intractable. The number of patients with age-associated diseases such as type 2 diabetes mellitus (T2DM), osteoporosis, Alzheimer's disease (AD), Parkinson's disease, atherosclerosis, and cancer has increased recently. Aging-related diseases are related to a deficiency of the immune system, which results from an aged thymus and bone marrow cells. Intra bone marrow-bone marrow transplantation (IBM-BMT) is a useful method to treat intractable diseases. This review summarizes findings that IBM-BMT can improve and treat aging-related diseases, including T2DM, osteoporosis and AD, in animal models.

Bone marrow-derived stem cells may modulate renal injury, but the effects may depend on the age of the stem cells. Here we investigated whether bone marrow from young mice attenuates renal aging in old mice. We radiated female 12-mo-old 129SvJ mice and reconstituted them with bone marrow cells (BMC) from either 8-wk-old (young-to-old) or 12-mo-old (old-to-old) male mice. Transfer of young BMC resulted in markedly decreased deposition of collagen IV in the mesangium and less β-galactosidase staining, an indicator of cell senescence. These changes paralleled reduced expression of plasminogen activator inhibitor-1 (PAI-1), PDGF-B (PDGF-B), the transdifferentiation marker fibroblast-specific protein-1 (FSP-1), and senescence-associated p16 and p21. __Tubulointerstitial and Glomerular Cells__ Tubulointerstitial and glomerular cells derived from the transplanted BMC did not show β-galactosidase activity, but after 6 mo, there were more FSP-1-expressing bone marrow-derived cells in old-to-old mice compared with young-to-old mice. Young-to-old mice also exhibited higher expression of the anti-aging gene Klotho and less phosphorylation of IGF-1 receptor β. Taken together, these data suggest that young bone marrow-derived cells can alleviate renal aging in old mice. Direct parenchymal reconstitution by stem cells, paracrine effects from adjacent cells, and circulating anti-aging molecules may mediate the aging of the kidney.

Recent research in gerontology shows that injecting young bone marrow into older mice can increase their remaining lifespan by up to 39%. While these findings highlight the exciting potential of regenerative medicine for life extension, further study is needed to determine how these biological mechanisms translate to human aging.

As we age, stem cells lose efficacy and ability to heal.